ER antagonists have demonstrated excellent curative efficacy in patients with ER-positive breast cancer (37); while ovarian cancer is also hormone-driven, the expression and role of hormone receptors in its pathogenesis remain poorly elucidated. This evidence concerns the gene ESR1 and ovarian carcinoma.